195 related articles for article (PubMed ID: 22933665)
1. Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness.
Capel E; Martrus G; Parera M; Clotet B; Martínez MA
J Gen Virol; 2012 Dec; 93(Pt 12):2625-2634. PubMed ID: 22933665
[TBL] [Abstract][Full Text] [Related]
2. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
van Maarseveen NM; Wensing AM; de Jong D; Taconis M; Borleffs JC; Boucher CA; Nijhuis M
J Infect Dis; 2007 Feb; 195(3):399-409. PubMed ID: 17205479
[TBL] [Abstract][Full Text] [Related]
3. An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs.
van Maarseveen NM; de Jong D; Boucher CA; Nijhuis M
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):162-8. PubMed ID: 16645546
[TBL] [Abstract][Full Text] [Related]
4. Significant changes in integrase-associated HIV-1 replication capacity between early and late isolates.
Capel E; Parera M; Clotet B; Martínez MA
Virology; 2013 Sep; 444(1-2):274-81. PubMed ID: 23880146
[TBL] [Abstract][Full Text] [Related]
5. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M
J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813
[TBL] [Abstract][Full Text] [Related]
6. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
[TBL] [Abstract][Full Text] [Related]
8. Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.
Sakai K; Chikata T; Brumme ZL; Brumme CJ; Gatanaga H; Oka S; Takiguchi M
Retrovirology; 2015 Nov; 12():98. PubMed ID: 26585907
[TBL] [Abstract][Full Text] [Related]
9. Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility.
Magiorkinis E; Paraskevis D; Detsika MG; Lu L; Magiorkinis G; Lazanas M; Imbrechts S; Van Laethem K; Vandamme AM; Pilot-Matias T; Molla A; Camacho RJ; Hatzakis A
AIDS Res Hum Retroviruses; 2011 Nov; 27(11):1223-9. PubMed ID: 21417947
[TBL] [Abstract][Full Text] [Related]
10. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
[TBL] [Abstract][Full Text] [Related]
11. Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.
Kagan RM; Cheung PK; Huard TK; Lewinski MA
Antiviral Res; 2006 Aug; 71(1):42-52. PubMed ID: 16600392
[TBL] [Abstract][Full Text] [Related]
12. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism.
Calazans A; Brindeiro R; Brindeiro P; Verli H; Arruda MB; Gonzalez LM; Guimaraes JA; Diaz RS; Antunes OA; Tanuri A
J Infect Dis; 2005 Jun; 191(11):1961-70. PubMed ID: 15871131
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.
Tanuri A; Vicente AC; Otsuki K; Ramos CA; Ferreira OC; Schechter M; Janini LM; Pieniazek D; Rayfield MA
Antimicrob Agents Chemother; 1999 Feb; 43(2):253-8. PubMed ID: 9925514
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.
Fonjungo PN; Mpoudi EN; Torimiro JN; Alemnji GA; Eno LT; Lyonga EJ; Nkengasong JN; Lal RB; Rayfield M; Kalish ML; Folks TM; Pieniazek D
J Clin Microbiol; 2002 Mar; 40(3):837-45. PubMed ID: 11880402
[TBL] [Abstract][Full Text] [Related]
15. The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication.
Margerison ES; Maguire M; Pillay D; Cane P; Elston RC
J Antimicrob Chemother; 2008 Apr; 61(4):786-91. PubMed ID: 18252693
[TBL] [Abstract][Full Text] [Related]
16. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
Pingen M; Wensing AM; Fransen K; De Bel A; de Jong D; Hoepelman AI; Magiorkinis E; Paraskevis D; Lunar MM; Poljak M; Nijhuis M; Boucher CA;
Retrovirology; 2014 Nov; 11():105. PubMed ID: 25575025
[TBL] [Abstract][Full Text] [Related]
17. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
Colonno R; Rose R; McLaren C; Thiry A; Parkin N; Friborg J
J Infect Dis; 2004 May; 189(10):1802-10. PubMed ID: 15122516
[TBL] [Abstract][Full Text] [Related]
18. The HIV type 1 protease L10I minor mutation decreases replication capacity and confers resistance to protease inhibitors.
Flor-Parra F; Pérez-Pulido AJ; Pachón J; Pérez-Romero P
AIDS Res Hum Retroviruses; 2011 Jan; 27(1):65-70. PubMed ID: 21142921
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
[TBL] [Abstract][Full Text] [Related]
20. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
